BCAL Diagnostics (ASX:BDX) Construction In Progress: A$0.00 Mil (As of Dec. 2025)


What is BCAL Diagnostics Construction In Progress?

BCAL Diagnostics ASX:BDX -3.70% Construction In Progress is A$0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics Construction In Progress Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Construction In Progress Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Construction In Progress
0.00 0.00 0.00 0.00

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCAL Diagnostics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of A$0.00 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Construction In Progress of A$0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Construction In Progress too high?
BCAL Diagnostics' current Construction In Progress is A$0.00 Mil.
How does BCAL Diagnostics' Construction In Progress compare to TMO and DHR?
BCAL Diagnostics' Construction In Progress of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Diagnostics & Research company?
A good Construction In Progress depends on the Medical Diagnostics & Research industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Construction In Progress is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Construction In Progress of A$0.00 Mil. The current Construction In Progress is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Construction In Progress is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.